ArticleNature biotechnology2026
Fast and accurate multiple-protein-sequence alignment at scale with FAMSA2.
Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Physiology, functional genomics, and proteomics ofApplied and environmental microbiology · 2026Article
- The last bacterial common ancestor encoded a complex flagellum.bioRxiv : the preprint server for biology · 2026Article
- Meta-virus resource (MetaVR): expanding the frontiers of viral diversity with 24 million uncultivated virus genomes.Nucleic acids research · 2026Article
- Extending Biopython to combine multiple sequence alignments with the same reference into a Multiple Sequence Alignment.microPublication biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
We introduce FAMSA2, an algorithm that produces high-accuracy multiple-protein-sequence alignments at high speed. Across structural, phylogenetic and functional benchmarks, FAMSA2 matches or exceeds the accuracy of state-of-the-art tools while running 400 times faster on average than existing aligners. By combining progressive alignment with medoid clustering-based guide tree construction and a dissimilarity measure derived from the longest common subsequence, it enables scalable alignment of massive protein families.
Identifiers
41981150What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.